Literature DB >> 28237201

Developing a Value Framework: The Need to Reflect the Opportunity Costs of Funding Decisions.

Mark Sculpher1, Karl Claxton2, Steven D Pearson3.   

Abstract

A growing number of health care systems internationally use formal economic evaluation methods to support health care funding decisions. Recently, a range of organizations have been advocating forms of analysis that have been termed "value frameworks." There has also been a push for analytical methods to reflect a fuller range of benefits of interventions through multicriteria decision analysis. A key principle that is invariably neglected in current and proposed frameworks is the need to reflect evidence on the opportunity costs that health systems face when making funding decisions. The mechanisms by which opportunity costs are realized vary depending on the system's financial arrangements, but they always mean that a decision to fund a specific intervention for a particular patient group has the potential to impose costs on others in terms of forgone benefits. These opportunity costs are rarely explicitly reflected in analysis to support decisions, but recent developments to quantify benefits forgone make more appropriate analyses feasible. Opportunity costs also need to be reflected in decisions if a broader range of attributes of benefit is considered, and opportunity costs are a key consideration in determining the appropriate level of total expenditure in a system. The principles by which opportunity costs can be reflected in analysis are illustrated in this article by using the example of the proposed methods for value-based pricing in the United Kingdom.
Copyright © 2017 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  QALYs; opportunity costs; value frameworks; value-based pricing

Mesh:

Year:  2017        PMID: 28237201     DOI: 10.1016/j.jval.2016.11.021

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  20 in total

1.  "Time Traveling Is Just Too Dangerous" but Some Methods Are Worth Revisiting: The Advantages of Expected Loss Curves Over Cost-Effectiveness Acceptability Curves and Frontier.

Authors:  Fernando Alarid-Escudero; Eva A Enns; Karen M Kuntz; Tzeyu L Michaud; Hawre Jalal
Journal:  Value Health       Date:  2019-05       Impact factor: 5.725

Review 2.  Cost-Effectiveness Thresholds: the Past, the Present and the Future.

Authors:  Praveen Thokala; Jessica Ochalek; Ashley A Leech; Thaison Tong
Journal:  Pharmacoeconomics       Date:  2018-05       Impact factor: 4.981

3.  Multi-criteria Decision Analysis Software in Healthcare Priority Setting: A Systematic Review.

Authors:  Alexander Moreno-Calderón; Thai S Tong; Praveen Thokala
Journal:  Pharmacoeconomics       Date:  2020-03       Impact factor: 4.981

4.  Supporting a review of the benefits package of the National Health Insurance Scheme in Ghana.

Authors:  Heleen Vellekoop; Emmanuel Odame; Jessica Ochalek
Journal:  Cost Eff Resour Alloc       Date:  2022-07-16

5.  Economic evaluation of interventions to address undernutrition: a systematic review.

Authors:  Francesco Ramponi; Wiktoria Tafesse; Susan Griffin
Journal:  Health Policy Plan       Date:  2021-05-17       Impact factor: 3.344

6.  The economic case for precision medicine.

Authors:  Sean P Gavan; Alexander J Thompson; Katherine Payne
Journal:  Expert Rev Precis Med Drug Dev       Date:  2018-01-08

7.  New Medicines in Wales: The All Wales Medicines Strategy Group (AWMSG) Appraisal Process and Outcomes.

Authors:  Alice Varnava; Robert Bracchi; Karen Samuels; Dyfrig A Hughes; Philip A Routledge
Journal:  Pharmacoeconomics       Date:  2018-05       Impact factor: 4.981

Review 8.  Value-based medicine in oncology: the importance of perspective in the emerging value frameworks.

Authors:  Alessandro Gonçalves Campolina
Journal:  Clinics (Sao Paulo)       Date:  2018-12-10       Impact factor: 2.365

9.  Impact of a Global Pandemic on Health Technology Assessment.

Authors:  Paula K Lorgelly; Amanda Adler
Journal:  Appl Health Econ Health Policy       Date:  2020-06       Impact factor: 2.561

10.  Introduction: priority setting in global health.

Authors:  David E Bloom; Daniel Cadarette; Rashmi Dayalu; Jessica Sullivan
Journal:  Cost Eff Resour Alloc       Date:  2018-11-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.